Rafael Holdings Inc Class B (RFL)
Rafael Holdings, Inc. is a common stock listing on the NYSE for a healthcare-focused company with activities in pharmaceuticals, medical devices, and real estate. The company primarily holds interests in clinical and early-stage pharmaceutical businesses in the United States and Israel. Its healthcare segment is centered on developing and commercializing therapies based on the metabolic differences between normal and cancer cells. Key programs include Trappsol Cyclo, a Phase 3 candidate being studied for Niemann-Pick Disease Type C1, and CPI-613 (devimistat), which is in Phase II clinical testing. Rafael Holdings also advances Promitil, a targeted mitomycin-C prodrug that has completed Phase 1A and 1B studies in patients with advanced cancers, and works on surgical and procedural devices such as an orthopedic arthroscopy instrument for carpal tunnel syndrome. The company was incorporated in 2017 and is headquartered in Newark, New Jersey.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-RFL
|
$1.48
|
-26.2% Downside
|
Overvalued
|
Not available
|
Not available
|
Fair
|
0.0%
|
November 4, 2026
|
1.4x
|
106.1x
|
104 M
|
79.53 M
|
0.6%
|
61.1%
|
-0.7
|
98.3%
|
